Amarin (NASDAQ:AMRN) Stock Rating Upgraded by Zacks Research
Zacks Research raised Amarin from a "strong sell" rating to a "hold" rating in a report on Wednesday...
MarketBeat·23d ago
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know
Amarin shares surge 37.7% in a year as restructuring, cost cuts and expanding Vazkepa partnerships for international growth fuel optimism.
Zacks·24d ago
Amarin (NASDAQ:AMRN) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut shares of Amarin from a "buy" rating to a "hold" rating in a research note on Saturday...
MarketBeat·30d ago
Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss
AMRN swings to Q4 profit and beats estimates, but revenues decline 21% as Vascepa sales slide and shares fall 9% on the mixed results.
Zacks·1mo ago
Amarin (NASDAQ:AMRN) Announces Earnings Results
Amarin (NASDAQ:AMRN - Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus...
MarketBeat·1mo ago
Amarin Q4 Earnings Call Highlights
Amarin (NASDAQ:AMRN) executives told investors that 2025 marked a substantial achievement year as the company advanced a strategic pivot toward a more partnered international commercial model and...
MarketBeat·1mo ago
Amarin Corp Earnings Report: Q4 Overview
read more...
Benzinga·1mo ago
Amarin (AMRN) to Release Quarterly Earnings on Wednesday
Amarin (NASDAQ:AMRN) will be releasing its Q4 2025 earnings before the market opens on Wednesday, February 25. (View Earnings Report at...